- AbbVie, Gilead, Janssen dazzle with Hep C data
- Merck data shake up all-oral hepatitis C race
- Reading between the lines of J&J's $1.75bn Alios buy
- Achillion, Regulus chase shorter HCV regimens, but can they beat Gilead?
- INTERVIEW: Champions Oncology champions personalized tumor models
- PROFILE: AstraZeneca's Mene Pangalos on yin and yang, not believing your own press, and his part in Soriot's vision